Journal
JOURNAL OF IMMUNOTHERAPY
Volume 28, Issue 4, Pages 389-395Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.cji.0000165353.19171.41
Keywords
prostate cancer; prostate-specific antigen; DNA vaccine; immune monitoring; immunotherapy
Categories
Ask authors/readers for more resources
Prostate cancer remains a leading cause of cancer illness and death among men in Europe. No curative treatment exists when the disease has spread beyond the prostate. Immunotherapy with DNA vaccines has emerged as a potential therapeutic approach for the induction of antitumor specific cytotoxic T lymphocytes. In this study six patients with hormone-refractory prostate cancer were monitored for their ability to mount PSA-specific cellular responses after receiving a pVAX/PSA DNA vaccine (patients 1-3, 100 mu g; patients 7-9, 900 mu g) with recombinant GM-CSF and IL-2 as adjuvants. IFN gamma ELISPOT showed that naturally processed PSA protein and PSA peptides are recognized by T cells in the blood of some prostate cancer patients after a PSA DNA vaccine. Analysis of other cytokines showed the production of IL-4 and IL-6 but importantly did not show an increase in the number of IL-10-producing cells after vaccination in any of the patients. The authors conclude that a pVAX/PSA DNA vaccine can induce PSA-specific cellular immune responses in patients with hormone-refractory prostate cancer, thus emphasizing the potential for PSA as a target molecule for the immunotherapy of prostate cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available